Navigation Links
Heart Hormones Beat Back Cancers in Mice

One hormone cured 80 percent of pancreatic cancers, two-thirds of breast cancers, researcher says

THURSDAY, Feb. 28 (HealthDay News) -- New research offers early evidence that hormones produced by the heart to control both blood pressure and volume could be harnessed to treat -- and possibly cure -- a wide range of cancers.

Following a month of intravenous treatment with any of four human cardiac peptide hormones, mice engineered to develop human pancreatic and breast cancer experienced dramatic results: On average, 54 percent of those with breast cancer and 37 percent of those with pancreatic cancer were cured, without tumor recurrence or treatment side effects.

Even tumor shrinkage among non-cured mice was striking, with size reductions of 90-plus percent. And a more detailed analysis, hormone-by-hormone, revealed even stronger anti-cancer properties among certain hormones. In such best-case scenarios, the most effective hormones provoked full tumor elimination -- without surgery, chemotherapy or any other additional treatment -- in two-thirds of the mice with breast cancer and 80 percent of the mice with pancreatic cancer.

"This raises hope for turning cancer -- even when not fully cured -- into a chronic disease," said study author Dr. David L. Vesely, director of the department of molecular pharmacology and physiology at the University of South Florida's Cardiac Hormone Center, in Tampa.

Vesely is scheduled to present his findings April 9 at the Experimental Biology annual conference in San Diego. The findings were originally published in the journal in vivo last year.

"For 350 years, the heart has been thought of simply as a pump," Vesely said. "But we now know it makes hormones that lower your blood pressure and get rid of salt and water. So, first we took four of them that all come from the same gene, and looked at them in laboratory cell cultures, and found that they essentially eliminated 97 percent of exposed cancer cells within 24 hours."

With funding largely from the U.S. Veteran's Administration, the research team then grew human cancer cells in 1-month-old male and female mice, focusing first on pancreatic cancer, which Vesely described as the "worst of all," given the fast pace of its development, its poor treatment track record, and a mean survival rate of just four months.

Nearly 34,000 Americans are diagnosed with pancreatic cancer each year, and 32,000 die of the disease annually.

Some of the pancreatic cancer mice received a saline solution, while others were exposed to a month-long regimen of one of four cardiac hormones: long acting natriuretic peptide (LANP), vessel dilator (VDL), kaliruretic peptide (KP), or atrial natriuretic peptide (ANP).

ANP was found to provide the best anti-cancer effect, eliminating tumors in four of five treated mice. Among those not fully cured, VDL provided the best cancer reduction -- bringing exposed tumors down to just 2 percent of their largest size.

After a year, the researchers found that all the cured mice remained cancer-free. Based on the fact that the normal life span for a mouse is about one year, Vesely and his colleagues concluded that all the treated mice ended up dying of old age, not cancer.

Vesely, who noted that his wife died of breast cancer about five years ago, then turned his focus to that cancer.

He said that in similar mouse experiments, treatments with VDL and KP hormones both produced a 67 percent tumor elimination rate.

"We never expected results this good, of course," he said. "And I don't want to get too carried away here. But if this works in humans, it would be spectacular. Because, of course, one out of every two families [experiences] cancer."

Human trials -- funded by the private San Diego-based firm Kalos Therapeutics -- are to begin within 12 to 18 months. If all goes well, Vesely predicted that a hormone treatment could become available within three years.

However, Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, cautioned that while the notion of a heart hormone cancer treatment has a "seductive" appeal, much more research is required.

"Unfortunately, in general, we see a lot of experiments that seem promising in test tubes and animals but for whatever reason don't translate into anything that has treatment benefit," he said. "And specifically, in this case, we're talking about normal hormones already in circulation in our body, and normal receptors on cancer cells.

"So, in a perhaps simplistic, but nonetheless important, way, the question then arises: Why do people get cancer in the first place if this hormonal mechanism is so effective?" Lichtenfeld said. "And I do not see that the researchers clearly suggest an underlying rational mechanism to explain why this would happen and work in humans.

"So, I understand here that a researcher has lost a wife and a mother to cancer, and I know it's personal," he acknowledged. "And I've certainly learned to never say never. But it would take considerably more replication of this work before I could say this theory will gain traction."

More information

For additional information on current cancer treatment options, visit the American Cancer Society.

SOURCES: Len Lichtenfeld, M.D., FACP, deputy chief medical officer, American Cancer Society, Atlanta; David L. Vesely, M.D., Ph.D., professor, medicine, department of internal medicine, and director, department of molecular pharmacology and physiology, University of South Florida Cardiac Hormone Center, Tampa; April 9, 2008, presentation, Experimental Biology meeting, San Diego

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Heart Hospital of Austins Expansion Increases Patient Capacity by 30 Percent
2. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
3. Age-Related Macular Degeneration Doubles Heart Attack and Stroke Risk
4. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
5. Specialized Care Essential for Women With Congenital Heart Disease Undergoing Pregnancy
6. New research indicates that a common heart drug
7. Statement of Robert Jarvik, MD, President and CEO of Jarvik Heart, Inc. Regarding the Lipitor DTC Advertisements
8. Adult Stem Cells Help Those With Immune Disorders, Heart Disease
9. Tips for Troublesome Medications, From the Harvard Heart Letter
10. VIDEO from Medialink and Siemens: NFL Stars Stress the Importance of a Healthy Heart
11. Heart attack rates fall following national smoking bans
Post Your Comments:
Related Image:
Heart Hormones Beat Back Cancers in Mice
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: